Glucagon promotes glucose mobilization in liver through glycogenolysis and gluconeogenesis ([@B1],[@B2]). Low blood glucose level normally triggers glucagon release from pancreatic α cells to prevent hypoglycemia caused by physical activity or excessive insulin actions ([@B1]--[@B3]). In type 1 diabetes (T1D), glucagon secretion becomes dysregulated. In early stage of T1D, α cells hypersecrete ([@B1],[@B2],[@B4]), causing excessive release of glucose, resulting in hyperglycemia and leading to long-term complications (blindness and organ failure). As diabetes progresses, α cells suffer from "hypoglycemic blindness," becoming sluggish in response to low glucose, exacerbating life-threatening acute hypoglycemic episodes ([@B3],[@B5]). No effective treatment has been developed to regulate glucagon secretion to combat hypoglycemic attacks.

Despite the importance of α cells in health and diabetes, this islet cell type has been relatively less studied than β cells. The primary reason for the slower investigation of α cells has been the low-yield isolation (∼20% of islet cells) and unreliable and inefficient identification of α cells when using conventional strategies of islet isolation and dispersion. We have recently developed the pancreas slice preparation to effectively circumvent these long-standing technical difficulties in assessing α-cell function ([@B6]), allowing reliable, efficient, and immediate examination of living α cells. Islet architecture within slices is well preserved, wherein α cells are retained in their cellulo-social environment, unperturbed by enzymatic and mechanical stresses inherent in conventional α-cell isolation procedures. α cells in pancreas slices were directly assessed via patch pipette. We demonstrated that every single α cell examined exhibited all the classical electrophysiological features of mouse α cells ([@B6]).

Although we and others have characterized normal α-cell biology in healthy rodent and human islets in some detail ([@B6],[@B7]), disruptions of α-cell biology caused by T1D have been minimally investigated. This is because T1D islets shrink in size and lose their compact islet architecture from immune-mediated β-cell ablation. This has rendered isolation of α cells from immunologically damaged islets by conventional methods technically unfeasible, thus hampering investigation of the α cell in its native disease state. We have now surmounted this problem by using the pancreas slice preparation in mice administered streptozotocin (STZ), which creates a state that in several aspects resembles T1D ([@B8],[@B9]). We used GluCre-ROSA26EYFP (GYY) mice, which express enhanced yellow fluorescence protein (EYFP) in α cells ([@B10]), to precisely identify α cells within the much reduced islet mass in the pancreas slice. α Cells within pancreas slices can be directly assessed by standard patch-clamp technique. Our combinatorial strategy allowed efficient investigation of α cells in disease (T1D) states that was not previously possible. We elucidated the alterations in ion channel properties in α cells that contribute to the intensified action potential (AP) firing and increased amplitude, which we postulate to lead to the clinically observed systemic hyperglucagonemia in early stage of T1D.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Animal care and all procedures were approved by the Institutional Animal Care and Use Committee of the University of Toronto. GYY mice were previously described by P.G. ([@B10]). GYY mice (16--20 weeks old) used in this study were of similar age at which NOD mice develop overt diabetes ([@B11]) and have fully developed pancreas with adult-size islets to ensure that islet shrinkage from STZ-induced β-cell death ([@B9]) remains visible within the pancreas slices.

Diabetes induction. {#s2}
-------------------

STZ (Bioshop, Burlington, Ontario, Canada) dissolved in sodium citrate buffer at a single daily dose of 40 mg/kg body mass was injected intraperitoneally into mice for 5 consecutive days and maintained for 4 weeks to allow animals to reach and surpass the peak incidence of β-cell apoptosis ([@B9]). Control animals were injected with citrate buffer. Mice were killed by cervical dislocation after the 4th week of STZ treatment for further experimentation.

For the intraperitoneal glucose tolerance test (IPGTT), 1.5 g glucose/kg body wt i.p. was injected into overnight-fasted (16 h) mice; blood glucose (glucometer, LifeScan, Burnaby, British Columbia, Canada) and glucagon were measured as indicated. For refed levels, mice fasted overnight (for fasting levels) were fed ad libitum with standard normal chow for 3 h. Blood samples were collected from femoral vein and loaded into capillary tubes coated with Kalium-EDTA (Microvette CB 3000; Sarstedt, Montreal, Quebec City, Canada); plasma was separated by centrifugation (10,000*g*, 10 min), and glucagon was assayed by RIA (Millipore, Etobicoke, Ontario, Canada).

Pancreatic α- and β-cell mass and insulin and glucagon content measurements. {#s3}
----------------------------------------------------------------------------

Islet cell mass was measured as previously described ([@B12]). Briefly, resected pancreata were fixed in 4% paraformaldehyde, embedded in paraffin, and thinly sectioned (5 μm thin) and then dewaxed, rehydrated, and immunostained with rabbit polyclonal anti-insulin (1:200; Biomeda) or antiglucagon (1:150; Vision Biosystems) antibodies and counterstained with hematoxylin-eosin. Slides were digitized on a bright-field scanner (×20 magnification), and quantitative analysis of stained areas was performed with ImageScope software (Aperio Technologies, Vista, CA) using a positive-pixel count algorithm.

For hormone content measurements, isolated pancreata were placed in acid-ethanol mixture (1.5% HCl, 70% EtOH), incubated overnight (−20°C), and then homogenized; the tissue levels of insulin and glucagon extracted by centrifugation (5,000*g*, 15 min) were then determined by RIA kits (Millipore) and normalized to total pancreatic protein content.

Pancreas slice preparation. {#s4}
---------------------------

Pancreas tissue slices were prepared as we recently reported ([@B6]). Electrophysiology was conducted an hour after preparation and completed within 5 h.

Immunofluorescence and electron microscopy. {#s5}
-------------------------------------------

Immunofluorescence microscopy was performed as described in our recent report ([@B6]) with the following primary antibodies (1:100; 3 h): mouse anti-glucagon or anti-insulin (Sigma) or anti-somatostatin (GeneTex, Irvine, CA). Electron microscopy was performed as we previously described ([@B13]). Glucagon granules (thus α cells) were identified by the typical appearance (large black dense core with thin halo) ([@B14],[@B15]). Glucagon dense core diameter was measured using NIH ImageJ software.

Electrophysiology. {#s6}
------------------

Electrophysiological recording was done as we described in our recent report using pancreatic slices ([@B6]), and here EYFP-expressing islet α cells in slices can be visualized and patched on. Standard whole-cell configuration was applied to all recordings, using a lock-in patch-clamp amplifier (EPC-9; HEKA Elektronik, Lambrecht/Pfalz, Germany). The signals were low-pass filtered and stored on the computer. Pulse (HEKA Electronik) was used for voltage pulse generation, data acquisition, and basic analysis, followed by further processing of the acquired data using Igor software. Voltage-clamp mode was used for recording all currents, and current-clamp mode was used for recording membrane potentials. The resting membrane potential was determined immediately after current-clamp mode was made, and spontaneous APs were observed without any current injection. The number of APs over recording periods of 30--120 s was counted using the event detection/threshold search program of Clampfit9 software (Axon), with a threshold range between −28.6 and −29.6 mV. The amplitude and firing frequency of APs were analyzed using Clampfit9 software. The firing frequency was normalized and presented as the number of APs per second (Hz). The extracellular solution has previously been described ([@B6]). The pipette solutions used were as follows: *1*) for recording Ca^2+^ and Na^+^ currents, in millimoles, 127 Cs-methanosulfonate, 8 CsCl, 10 HEPES, 20 tetraethylammonium-Cl, 2 MgCl~2~, 2 Na~2~ATP, and 0.05 EGTA; *2*) for recording K^+^ current and depolarization-evoked cumulative membrane capacitance (Δ*C*~m~), in millimoles, 140 KCl, 10 HEPES, 2 MgCl~2~, 2 Na~2~ATP, and 0.05 EGTA; and *3*) for membrane potential recording, the same pipette solution was used as in no. 2. pH of all solutions was 7.2; osmolality was 300 ± 10 mOsm kg^−1^. All recordings were performed at 32°C. The pipette resistance ranged between 2 and 4 MΩ. All chemicals were from Sigma.

RESULTS {#s7}
=======

STZ induction of diabetes in GYY mice. {#s8}
--------------------------------------

Fasting blood glucose level in STZ-treated GYY mice increased at 2 weeks ([Fig. 1*A*](#F1){ref-type="fig"}) and refed blood glucose level at 1 week ([Fig. 1*B*](#F1){ref-type="fig"}) posttreatment. Fasting ([Fig. 1*C*](#F1){ref-type="fig"}) and refed ([Fig. 1*D*](#F1){ref-type="fig"}) plasma glucagon levels rose to abnormal levels at 3 weeks and 1 week post-STZ treatment, respectively. The increased plasma glucagon levels ([Fig. 1*C* and *D*](#F1){ref-type="fig"}) contributed in part to the observed hyperglycemia ([Fig. 1*A* and *B*](#F1){ref-type="fig"}) in STZ-treated GYY mice. At 4 weeks post-STZ treatment, the mice showed the stable diabetes phenotype characterized as high and sustained fasting blood glucose ([Fig. 1*A*](#F1){ref-type="fig"}) (control 6.1 ± 0.3 mmol/L, *n* = 10, vs. STZ 11.7 ± 1.7 mmol/L, *n* = 12), refed blood glucose ([Fig. 1*B*](#F1){ref-type="fig"}) (control 10.1 ± 0.5 mmol/L vs. STZ 28.7 ± 1.5 mmol/L), fasting plasma glucagon ([Fig. 1*C*](#F1){ref-type="fig"}) (control 70.3 ± 4.3 pg/mL vs. STZ 120.9 ± 24.2 pg/mL), and fed plasma glucagon ([Fig. 1*D*](#F1){ref-type="fig"}) (control 113.9 ± 31.8 pg/mL vs. STZ 220.1 ± 32.7 pg/mL) compared with the controls. The STZ-GYY mice also experienced mild weight loss ([Fig. 1*E*](#F1){ref-type="fig"}) and developed glucose intolerance (IPGTT) ([Fig. 1*F*](#F1){ref-type="fig"}) at 4 weeks after treatment. We thus selected mice at 4 weeks post-STZ treatment for all the subsequent in vitro and electrophysiological experiments.

![STZ-induced diabetes in GYY mice. Time courses of fasting (*A*) and refed (*B*) blood glucose levels, fasting (*C*) and refed (*D*) plasma glucagon levels, and body weight (*E*). The measurements were made periodically from the control and STZ-treated mice before (0 week) and over the course of 4 weeks after the first day of STZ injection. All data are plotted as means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 (control mice, *n* = 10; STZ-treated mice, *n* = 12). *F*: Time course of IPGTT. Blood glucose levels were measured from the control (*n* = 10) or STZ-treated (*n* = 16) mice 4 weeks postinjection (\*\*\**P* \< 0.001). Conc., concentration.](519fig1){#F1}

Effects of STZ-induced diabetes on islet morphology, α- and β-cell mass, and glucagon and insulin content. {#s9}
----------------------------------------------------------------------------------------------------------

Confocal microscopy analysis of pancreas slices demonstrated a redistributed pattern of insulin ([Fig. 2*B*i and *B*i'](#F2){ref-type="fig"} \[cells in red\]) and glucagon ([Fig. 2*B*ii and *B*ii'](#F2){ref-type="fig"} \[cells in both red and yellow\]) staining in islets of STZ-treated mice compared with controls. Control islets showed glucagon-labeled α cells resided along the islet periphery ([Fig. 2*A*i and 2*A*i'](#F2){ref-type="fig"} \[cells in yellow\] and [2*A*ii and 2*A*ii'](#F2){ref-type="fig"} \[cells in both yellow and red\]) and the larger mass of insulin-labeled β cells occupied the islet core ([Fig. 2*A*i and *A*i'](#F2){ref-type="fig"}, red). Total pancreatic α- and β-cell masses were determined by immunohistochemical quantification of insulin- and glucagon-positive staining areas (see [[research design and methods]{.smallcaps}](#s1){ref-type="sec"}), normalized to entire pancreas cross-sectional tissue area; the resulting values were then multiplied by the wet pancreas weight of each mouse. Mean pancreas wet weights were similar (control 0.216 ± 0.006 g vs. STZ mice 0.251 ± 0.05 g; *P* = 0.43). The relative ratio of α cell to total pancreatic tissue area was also similar (control 0.0029 ± 0.0005 vs. STZ 0.0024 ± 0.0002; *P* = 0.36). However, the ratio of β cell to total pancreatic tissue area was reduced in STZ-treated mice (control 0.0152 ± 0.0017 vs. STZ 0.0048 ± 0.0006; *P* = 0.0005). STZ treatment reduced β-cell mass by 71% ([Fig. 2*C*](#F2){ref-type="fig"}), but there was no difference in α-cell mass between STZ and control mice ([Fig. 2*D*](#F2){ref-type="fig"}).

![Comparison of islet morphology between control and STZ-treated GYY mice. *A* and *B*: Representative images of islets of control (*A*) and STZ-treated (*B*) GYY mice embedded in pancreas slices. Images in the *right panels* (*Ai'*, *Aii'*, *Bi'*, and *Bii'*) were magnified from the inset white boxes in the *left panels* (*Ai*, *Aii*, *Bi*, and *Bii*). In control islets (*A*), α cells expressing EYFP (in the cytosol) stained with glucagon located in the periphery of the cells (*Aii* and *Aii'*: red, glucagon; yellow, EYFP). Insulin-labeled β cells (*Ai* and *Ai'*: red, insulin; yellow, EYFP) are abundant in the islet core. In STZ-treated mice, the majority of β cells were ablated by STZ treatment (*Bi* and *Bi'*: red, insulin; yellow, EYFP) with α cells redistributed to the islet core (*Bii* and *Bii'*: red, glucagon; yellow, EYPF). Similar to control islets, these α cells in STZ-treated mice expressing EYFP also exhibit glucagon staining in the periphery of the cells. (*n* = 5 mice in each group.) *C* and *D*: Total pancreatic β-cell (*C*) and α-cell (*D*) masses in the control and STZ groups determined 4 weeks after injection (*n* = 5 mice in each group). *E* and *F*: Total pancreatic insulin (*E*) and glucagon (*F*) content in the control and STZ groups measured at 4 weeks after STZ treatment. (\**P* \< 0.05, \*\*0.01, and \*\*\*0.001, respectively; *n* = 5 mice in each group.) *G*: Representative images of pancreas slice prepared from control (*a* and *b*) and STZ (*c* and *d*) mice viewed under bright-field (*a* and *c*) or EYFP-specific (*b* and *d*) filter. In both islets, a patch pipette (white arrow) is shown approaching a cell on the islet edge, which expresses EYFP. (A high-quality digital representation of this figure is available in the online issue.)](519fig2){#F2}

Total pancreatic glucagon and insulin content normalized to the total protein content of each pancreas showed that STZ mice had increased mean pancreatic glucagon content (STZ mice 440,747 ± 55,473 pg vs. control 103,398 ± 5,999 pg; *n* = 5 mice/group, *P* = 0.0002) and reduced mean insulin content (STZ mice 4,091 ± 564 ng vs. control 68,518 ± 5579 ng; *P* = 0.000003). Mean pancreatic protein content was similar (STZ mice 23,590 ± 470 μg vs. control 22,621 ± 473 μg; *P* = 0.18). In the STZ-treated mice group, total pancreatic insulin content per protein content was severely reduced because of β-cell destruction ([Fig. 2*E*](#F2){ref-type="fig"}) (control 3.02 ± 0.22 ng/µg vs. STZ 0.17 ± 0.02 ng/µg). Surprisingly, total pancreatic glucagon content per protein content in the STZ group was remarkably elevated to fourfold higher than in control mice ([Fig. 2*F*](#F2){ref-type="fig"}) (control 4.59 ± 0.32 vs. STZ 18.71 ± 2.19 pg/µg).

STZ-treated GYY mouse α cells are larger and have larger glucagon granules. {#s10}
---------------------------------------------------------------------------

The above results demonstrated that STZ induction of diabetes did not alter α-cell mass but increased glucagon content, which taken along with the increased plasma glucagon led us to postulate that each α cell in the STZ-treated mouse islet contains and releases more glucagon. We directly tested this hypothesis by two strategies: *1*) single α-cell ∆*C*~m~ induced by serial membrane depolarization and *2*) ultrastructural analysis of α-cell glucagon granules. Since GYY mice express EYFP in pancreatic α cells ([@B10],[@B16]), this allows α cells to be visualized within pancreas slices under a fluorescence microscope ([Fig. 2*G*b and *G*d](#F2){ref-type="fig"}) and be accurately reached with the patch pipette ([Fig. 2*G*a and *G*c](#F2){ref-type="fig"}). We performed electrophysiological characterizations on every recorded α cell as previously reported ([@B6]) to further confirm their identity.

A train of depolarizing pulses trigger Δ*C*~m~ in α cells due to Ca^2+^ influx and subsequent glucagon granule exocytotic fusion, as an indicator of α-cell secretion ([@B6]). [Figure 3*A*](#F3){ref-type="fig"} shows mean Δ*C*~m~ in α cells of control and STZ mice in response to 50 pulses depolarizing from −80 to 10 mV, which was higher in STZ-treated mice α cells. [Figure 3*B*](#F3){ref-type="fig"} summarizes the cumulative Δ*C*~m~ triggered at the 50th pulse to be higher in α cells of STZ-treated mice (control 12.2 ± 1.9 fF/pF vs. STZ 19.9 ± 3.2 fF/pF; *P* \< 0.05). Interestingly, the resting *C*~m~ of α cells ([Fig. 3*C*](#F3){ref-type="fig"}) measured before the depolarization stimuli, which is proportional to cell membrane area, was also slightly increased in STZ α cells (5.33 ± 0.3 fF/pF) compared with control α cells (4.61 ± 0.18 fF/pF; *P* = 0.0496).

![α-Cell glucagon granule exocytosis in STZ-treated GYY mice. *A*: Mean α-cell capacitance (Δ*C*~m~) triggered by a train of 50 depolarizing pulses from −80 mV (60 ms) to 10 mV (40 ms). \**P* \< 0.05; *n* = 27 cells from five control mice (●), *n* = 30 cells from four STZ mice (○). For recording conditions, see [[research design and methods]{.smallcaps}](#s1){ref-type="sec"}. *B*: Δ*C*~m~ elicited by the 50th depolarizing pulses in *A* (\**P* \< 0.05; *n* = 27 cells from five control mice, *n* = 30 cells from four STZ mice). *C*: Mean resting *C*~m~ of α cell, as a measure of the cell size. \**P* \< 0.05; *n* = 27 cells from five control mice, *n* = 30 cells from four STZ mice. *D* and *E*: Representative electron micrographs of α cells of control (*D*) and STZ-treated (*E*) mice. *D*' and *E*': Magnified images of the white rectangles in *D* and *E*. *F* and *G*: Gaussian distribution curve of glucagon granule dense core diameters of control (*F*) (*n* = 2,642 granules from 18 cells of three control mice) and STZ-treated (*G*) (*n* = 3,679 granules from 32 cells of three STZ-treated mice) mice. Mean number of granules (*H*) and mean dense core diameter (*I*) of glucagon granules in α cells of control and STZ mice obtained from the same datasets in *F* and *G*, respectively. \*\*\**P* \< 0.001.](519fig3){#F3}

The increases in both evoked and resting *C*~m~ in α cells of STZ-treated mice suggest the possibility of an increase in the number and/or size of glucagon granules fusing with plasma membrane. To assess this possibility, we performed electron microscopy analysis of the islet α cells ([Fig. 3*D*](#F3){ref-type="fig"}, control α cells; [Fig. 3*E*](#F3){ref-type="fig"}, STZ-treated α cells). The corresponding enlarged views of the indicated areas ([Fig. 3*D*](#F3){ref-type="fig"}' and *E*') show the glucagon dense core granules to be obviously larger in STZ α cells. Quantitative analysis shows that the mean diameter of granule dense core ([Fig. 3*I*](#F3){ref-type="fig"}) was indeed larger in α cells of STZ-treated mice (228.50 ± 1.17 nm, *N* = 3,679 granules/32 cells; *P* \< 0.0001) than control α cells (195.48 ± 0.94 nm, *N* = 2,642/18 cells). Analysis of granule distribution shows a shift in the overall sizes of glucagon granules of STZ-treated mice ([Fig. 3*G*](#F3){ref-type="fig"}) compared with control α cells ([Fig. 3*F*](#F3){ref-type="fig"}), with corresponding modes (peak of the curves relative to the vertical dotted line) of 209 ± 1.56 and 184 ± 1.5 nm, respectively. However, the number of glucagon granules per α cell determined as mean glucagon granules/cell area ([Fig. 3*H*](#F3){ref-type="fig"}) was similar (control 3.0 ± 0.3 granules/μm^2^ vs. STZ 2.3 ± 0.3 granules/μm^2^). If one assumes that dense core granules are perfect spheres and sizes of α cells are similar between the two groups, the volume of glucagon in α cells can be calculated by the equation *V* = 4/3 π*r*^3^, where *r* is the radius of the dense core. Accordingly, the volume of glucagon of an α cell of STZ-treated mice can be estimated to be 1.6 times larger than control α cells. Since resting *C*~m~ measurement ([Fig. 3*C*](#F3){ref-type="fig"}) suggested an increased cell size in STZ-treated α cells, glucagon contained in α cells of STZ-treated mice should be \>1.6 times larger than control α cells.

Nonetheless, this increased glucagon content in glucagon granules may not be sufficient to fully account for the four times increase in pancreatic glucagon content in STZ-treated mice. Taken along with the similar sizes of α-cell mass, our results suggest that the excess glucagon content per α cell is likely also contributed by accumulation of glucagon content in other compartments (endoplasmic reticulum, Golgi, etc.), which in turn suggests an increased in glucagon protein synthesis (which we currently don't have the technical ability to determine).

Voltage-gated K^+^ currents. {#s11}
----------------------------

Voltage-gated K^+^ (K~V~) channels, shown to play a positive role in regulating glucagon secretion ([@B17]), were therefore assessed in α cells of control and STZ-treated mice ([Fig. 4](#F4){ref-type="fig"}). In the control group (15 cells), a transient K~V~ current became detectable when depolarizing membrane potential to −30 mV and above ([Fig. 4*A*](#F4){ref-type="fig"} \[control\]); this current inactivated rapidly (∼30 ms). Further depolarizing the membrane to −20 mV and higher voltages evoked an additional sustained K~V~ component (indicated in [Fig. 4*A*](#F4){ref-type="fig"}). In the STZ group (14 cells), α-cell transient K~V~ current was notably suppressed ([Fig. 4*A*](#F4){ref-type="fig"} \[STZ\]). [Figure 4*B*](#F4){ref-type="fig"} summarized the transient K~V~ current density, which was significantly suppressed in STZ α cells when membrane potential was depolarized to 20 mV (control 281.8 ± 20.2 pA/pF vs. STZ 241.8 ± 11.4 pA/pF; *P* \< 0.05) and higher voltages. [Figure 4*C*](#F4){ref-type="fig"} summarized K~V~-sustained current density, which was comparable between the two groups.

![Voltage-gated K^+^ current in α cells of STZ-treated GYY mice. *A*: Representative whole-cell voltage-gated K^+^ current traces evoked by a series of 500-ms pulses (*top panel*). *Top panel*: Step-depolarizing protocol from a holding potential of −80 to 80 mV in 10-mV increments. (For clarity, traces evoked between −70 and −50 mV were not shown.) For recording conditions, see [[research design and methods]{.smallcaps}](#s1){ref-type="sec"}. *B* and *C*: Current-voltage (I--V) relationships. K~V~ transient (*B*) (peak current evoked within the first 100 ms) and K~V~ sustained (*C*) (mean current of the last 100 ms) current density was plotted against the applied voltages (*n* = 15 cells from two control mice, *n* = 14 cells from two STZ-treated mice) (\**P* \< 0.05; \*\**P* \< 0.01). Note that the K~V~ transient current density was reduced in the STZ group at ≥20 mV, whereas K~V~ sustained current density remained similar to that in controls.](519fig4){#F4}

Voltage-gated Ca^2+^ currents. {#s12}
------------------------------

It is possible that α cells in STZ-treated mice might have larger Ca^2+^ influx to in part explain the larger *C*~m~ increase. We thus examined whether there is alteration in the properties of Ca^2+^ channels. In all the experiments, tetrodotoxin (0.1 μg/mL) was added in the bath solution to block voltage-gated Na^+^ current. A 300-ms ramp protocol running from −80 to 60 mV was applied to each α cell to trigger low voltage--activated (LVA) and high voltage--activated (HVA) Ca^2+^ currents. α cells from STZ-treated mice possessed LVA and HVA Ca^2+^ current density similar to that of control mouse α cells ([Fig. 5*A*--*H*](#F5){ref-type="fig"}) (mean LVA control −3.14 ± 0.51 pA/pF vs. STZ ~~−~~2.85 ± 0.25 pA/pF, *P* \> 0.5; mean HVA control −7.10 ± 1.15 pA/pF vs. STZ −6.84 ± 0.82 pA/pF, *P* \> 0.5; *n* = 8 control cells and 16 STZ cells). Since T-type current likely contributes to LVA Ca^2+^ currents, we added NiCl (100 μmol/L) to block T-type Ca^2+^ channels ([Fig. 5*A* and *B*](#F5){ref-type="fig"} \[control\] and [Fig. 5*E* and *F*](#F5){ref-type="fig"} \[STZ\]). As anticipated, NiCl reduced LVA Ca^2+^ current amplitude in α cells of controls from 3.14 ± 0.51 to 1.87 ± 0.42 pA/pF ([Fig. 5*A* and *B*](#F5){ref-type="fig"}) (*n* = 6 cells) and that of STZ-treated mice from 2.51 ± 0.25 to 0.84 ± 0.29 pA/pF ([Fig. 5*E* and *F*](#F5){ref-type="fig"}) (*n* = 11 cells). For confirmation of the HVA Ca^2+^ current component, CdCl~2~, a broad-spectrum HVA Ca^2+^ channel blocker, was applied. The inward current component, peaked at 0--10 mV in both control ([Fig. 5*C* and *D*](#F5){ref-type="fig"} \[*n* = 6 cells\]) and STZ ([Fig. 5*G* and *H*](#F5){ref-type="fig"} \[*n* = 6 cells\]) cells, was completed abolished by Cd^2+^ (200 μmol/L). Taken together, our results indicate that Ca^2+^ current in α cells is contributed by predominantly HVA channels, consistent with previous reports ([@B18],[@B19]). Both current amplitudes of HVA- and T-type channels were not significantly altered by STZ treatment.

![Voltage-gated LVA and HVA Ca^2+^ current in α cells of STZ-treated GYY mice. Tetrodotoxin (TTX) (0.1 μg/mL) was added to block voltage-gated Na^+^ channels in all recordings. Representative I--V curves evoked by a 300-ms ramp protocol demonstrating LVA (*A*) and HVA (*C*) components in control cells. NiCl (100 μmol/L) selectively blocked the LVA component, whereas CdCl~2~ (200 μmol/L) blocked HVA components. The data are summarized in *B* and *D*. For recording conditions, see [[research design and methods]{.smallcaps}](#s1){ref-type="sec"}. Representative I--V curves evoked by the ramp protocol demonstrating LVA (*E*) and HVA (*G*) components in STZ-treated cells. The data are summarized in *F* and *H*.](519fig5){#F5}

Voltage-gated Na^+^ currents. {#s13}
-----------------------------

Current-voltage dependence of voltage-gated Na^+^ inward current was assessed by using Cs^2+^-based tetraethylammonium-containing pipette solution to block K~V~ currents ([Fig. 6*A*](#F6){ref-type="fig"}). Na^+^ current can be elicited in every α cell of both control and STZ groups from −80-mV holding potential. Na^+^ inward current became detectable when depolarizing membrane potential to higher than −30 mV ([Fig. 6*A*](#F6){ref-type="fig"}). Dotted lines indicate zero current level. The peaked Na^+^ current amplitudes were −59.6 ± 6.2 pA/pF in controls and −78.4 ± 9.9 pA/pF in the STZ group upon depolarizing to 0 mV ([Fig. 6*B* and *C*](#F6){ref-type="fig"}). Na^+^ channel I--V relationships of both control and STZ α cells exhibited a U-shaped voltage-dependent activation ([Fig. 6*B*](#F6){ref-type="fig"}). Upon depolarizing to between −20 and 0 mV, α cells of the STZ group revealed significantly larger Na^+^ current density than controls (*P* \< 0.05). Peak Na^+^ current was reached between −10 and 0 mV in both the STZ and control groups. Steady-state Na^+^-channel inactivation was examined by a depolarizing pulse to 0 mV from a set of conditioning pulses between −150 and 0 mV in 10-mV increments ([Fig. 6*D*](#F6){ref-type="fig"}). In both control and STZ-group α cells, steady-state Na^+^ channel inactivation curve showed no difference; Na^+^ channel half-inactivation potential (*V*~1/2~) in the control and STZ groups was −37.2 and −36.4 mV, respectively ([Fig. 6*E*](#F6){ref-type="fig"}).

![Voltage-gated Na^+^ current in α cells of STZ-treated GYY mice. *A*: Whole-cell Na^+^ current. Representative traces of Na^+^ current of a control α cell elicited by a 500-ms step depolarizing protocol from −80 to 40 mV in 10-mV increments at a holding potential of −80 mV (*top panel*). The magnified Na^+^ current in a larger time scale is shown in the inset box. Numbers in the box denote the applied voltage (mV). For recording conditions, see [[research design and methods]{.smallcaps}](#s1){ref-type="sec"}. *B*: I--V relationship of the Na^+^ current. The peak Na^+^ current measured from the cells in the control and STZ groups is presented as the current density and plotted against the applied voltage. The current density was larger in the STZ group at the given voltage pulses. \*Difference between the two groups was statistically significant (*P* \< 0.05; control, *N* = 34 cells from six mice; STZ, *N* = 37 cells from four mice). *C*: Representative traces of Na^+^ current recorded from α cells in the control and STZ groups. The current was elicited by a step pulse from −80 to 0 mV. *D*: Steady-state inactivation properties of the Na^+^ channel. Representative current traces of a control cell were elicited by a standard two-pulse protocol (*top panel*). The magnified Na^+^ currents elicited by the test pulses are shown in the inset box. Numbers indicated by arrows in the box denote the test pulse voltage (mV). *E*: Steady-state Na^+^ current inactivation curves from control and STZ groups. The *V*~1/2~ is indicated by dashed lines. No differences were found between the control and STZ groups (*P* \> 0.05; control, 34 cells from six mice; STZ, 37 cells from four mice). All of the recording were performed in Na^+^ 125 mmol/L in bath solution with Cs^+^ (135 mmol/L)-based pipette solution.](519fig6){#F6}

Membrane electrical property of α cells in control and STZ-treated mice. {#s14}
------------------------------------------------------------------------

Voltage-gated Na^+^ and K^+^ currents are important components contributing to α-cell AP firing. We demonstrated that in the STZ-treated group, the Na^+^ and K~V~ current densities are, respectively, increased and decreased, and, thus, AP firing pattern in α cells could be subsequently altered. We performed current-clamp recordings to test this postulation.

After breaking the seal between pipette and cell membrane in voltage-clamp mode, current clamp mode was immediately switched to record resting membrane potential and regenerative AP firing. To confirm the α-cell type in addition to their cellular EYFP ([@B6]), a short step protocol (\<4.5 s) was executed in voltage-clamp mode to determine the Na^+^-channel *V*~1/2.~

The resting membrane potential in α cells was not significantly different between the two groups (control −56.3 ± 1.4 mV vs. STZ −54.0 ± 2.9 mV) ([Fig. 7*C*](#F7){ref-type="fig"}). Robust AP firing was recorded in control ([Fig. 7*A*](#F7){ref-type="fig"}) and STZ-treated mouse α cells ([Fig. 7*B*](#F7){ref-type="fig"}). In control cells, AP fires spontaneously at a mean firing frequency of 0.68 ± 0.16 Hz ([Fig. 7*D*](#F7){ref-type="fig"}): initiating at approximately −45 mV, giving rise to mean upstroke amplitude of 33.7 ± 1.8 mV, which then rapidly repolarized ([Fig. 7*A*](#F7){ref-type="fig"}'). In α cells of STZ-treated mice, AP firing frequency was significantly higher (2.33 ± 0.27 Hz; *P* \< 0.0001) ([Fig. 7*B* and *D*](#F7){ref-type="fig"}), along with higher mean AP amplitudes (control 33.7 ± 1.8 mV vs. STZ 54.2 ± 2.1 mV, *P* \< 0.0001).

![α-Cell membrane electrical activity of control and STZ-treated mice. *A*: A representative α-cell membrane potential trace of a control mouse by current-clamp recording. For recording conditions, see [[research design and methods]{.smallcaps}](#s1){ref-type="sec"}. *A*': A single AP profile in *A* shown in a larger time scale. Dashed line depicts zero current level in all graphs. *B*: A representative α-cell membrane potential trace from an STZ-treated mouse. Note the larger AP amplitudes and more intense frequency of AP firing in the STZ group compared with the control (*A*). *B*': An AP profile in *B* shown in a larger time scale. *C*: Mean resting membrane potential recorded in α cells of control (black bar) and STZ-treated (white bar) mice. The data are presented as means ± SEM. (*P* \> 0.05; 19 cells of seven control mice and 34 cells of four STZ-treated mice.) *D*: Summary of α-cell AP firing frequency between control and STZ-treated mice. The mean ± SEM firing frequency increased significantly in the STZ group (15 cells from seven control mice and 27 cells from three STZ-treated mice, \*\*\**P* \< 0.001).](519fig7){#F7}

DISCUSSION {#s15}
==========

α Cells in healthy GYY mice expressed voltage-gated Na^+^, Ca^2+^, and K^+^ currents and Δ*C*~m~ when depolarized. These electrophysiological properties are comparable with their background C57BL/6J and NMRI mice ([@B6],[@B10]), validating GYY mice as an excellent model to study α-cell physiology and pathophysiology. STZ-treated GYY mouse α cells exhibited hyperglucagonemia and consequent hyperglycemia. Hyperglucagonemia in STZ-treated GYY mice resulted from elevated total pancreatic glucagon content partly contained in the larger glucagon granules, which are expected to effect more stimulated-glucagon granule release. Since total pancreatic α-cell mass of STZ-treated GYY mice remained unchanged while total pancreatic glucagon content was fourfold elevated, it can be predicted that the larger glucagon granules containing some of the excess glucagon are exocytosed in response to every stimulus (i.e., low glucose) on each α cell, culminating in the observed hyperglucagonemia. This is evident by the higher *C*~m~ increase in STZ-treated mouse α cells when electrically depolarized. Our results in the STZ-treated mouse are similar to a recent report showing that genetically induced near-complete β-cell ablation led to increased α-cell glucagon content and also consequent hyperglucagonemia ([@B20]).

What are the electrical and/or cellular properties of α cells in STZ-treated mice that contributed to the observed hyperglucagonemia? First, AP firing frequency and amplitude in α cells of STZ-treated mice were more intensified, which would be expected to lead to more glucagon secretion. Whereas these changes in AP are expected to increase Ca^2+^ influx, we showed that whole-cell Ca^2+^ current was not different between STZ-treated and control mice. The increased AP could be attributed to changes in Na^+^ and K~V~ currents; in fact, STZ-treated mouse α cells exhibited larger Na^+^ current density and lower K^+^ current density (discussed below). Second, the higher *C*~m~ increase in STZ-treated mouse α cells induced by serial membrane depolarization can be attributed to the larger glucagon granules exocytosing at the same Ca^2+^ stimulus, thus emptying a larger cargo of glucagon than control mouse α cells. We showed that K~V~ transient current within healthy α cells is rapidly activated and inactivated, which is similar to the A-type K current we ([@B19]) and Rorsman and colleagues ([@B21]) have previously demonstrated in rodent α cells. Consistent with the consensus thinking, this would suggest that the reduced K~V~ transient current in α cells of STZ-treated mice was likely the A-type K current, contributing to the observed increased AP firing rate and amplitude ([@B21],[@B22]). However, recent reports showed that the K~V~ transient currents in both α- and β cells could also be contributed by large-conductance Ca^2+^-activated voltage-gated K^+^ currents (BK currents) ([@B7],[@B23],[@B24]), and, hence, reduced BK currents could also contribute to increased secretion and potentiated AP amplitude ([@B7],[@B20],[@B21],[@B25]). In STZ-treated mouse α cells, we noted the increased Na^+^ current density coincided with an increase in AP amplitude. As expected ([@B7],[@B21]), tetrodotoxin (an Na^+^-channel blocker) inhibited glucagon secretion in both STZ and control pancreas slices (data not shown). These findings are consistent with the notion that Na^+^ current influx-evoked AP trigger glucagon granule exocytosis.

What are the factors in STZ-treated mice that would cause suppression of K~V~-transient current and enhancement of Na^+^ current in α cells? One possibility is the loss of paracrine regulation emanating from β-cell destruction, and these paracrine factors include insulin, γ-aminobutyric acid, and zinc ([@B26]--[@B30]) and possibly other factors. A second possibility is inflammatory cytokines secreted by cytotoxic T cells recruited during β-cell destruction induced by STZ, such as interleukin 1β, interferon-γ, and tumor necrosis factor-α ([@B26]), which could conceivably activate or sensitize some α-cell ion channels. In fact, several reports have shown that in colitis and ileitis animal models, release of inflammatory cytokine is associated with hyperexcitability of colonic dorsal root ganglion neurons, which were attributed to alterations in K~V~ and Na^+^ currents ([@B31]--[@B35]). These findings are consistent with our findings in α cells in the STZ-induced diabetes mouse model. Diabetes development in the STZ-treated mouse model ([@B8]) or in patients with T1D ([@B36]) is associated with similar inflammatory processes in the islets (i.e., insulitis), wherein cytotoxic T cells are recruited and release inflammatory cytokines ([@B26]) that can be predicted to perturb ion channels in α cells, perhaps in a manner similarly observed in this study.

The STZ-induced diabetes animal model in several respects mimics human T1D. STZ is transported into the β cell through Glut2 transporters, inducing cytotoxicity by oxidative damage and autoimmune reaction ([@B8]), including lymphocyte infiltration leading to insulitis and β-cell apoptosis ([@B9]). Because α cells express only Glut1 or Glut5 transporters ([@B37],[@B38]), they are likely protected from STZ-mediated destruction, hence, the normal α-cell mass observed in this study. Furthermore, the complement of ion channel expression and functional properties of α cells in STZ-treated mice was comparable with α cells from control mice. Nevertheless, additional models of T1D, including noninflammatory (genetic ablation of β cells) ([@B20]) and autoimmune inflammatory (NOD mouse) models, should be tested in future studies to further validate the findings presented in this study and to explore the contributions of paracrine and inflammatory factors that may contribute to the perturbation of α cells in T1D. Insights from such studies could lead to strategies to correct such perturbation, thereby normalizing α-cell glucagon secretory responses ([@B39]).
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